MP

Mahesh Pareek

Active Director Director DIN 09544188
DIN 09544188 First appointment Apr 2022 Primary industry Trading
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2022
Shareholding value •••• Premium profile

About Mahesh Pareek

Data last updated:

Mahesh Pareek is a Director at Kenmed Pharma Private Limited (since 2022). The company operates in Trading. Kenmed Pharma Private Limited reported revenue of ₹1.79 Cr (FY 2024).

DIN 09544188
Primary Designation Director
Industry Trading
First Appointment 01 Apr 2022
Oldest Company Age 5 yrs
Largest company Kenmed Pharma Private Limited · ₹1.79 Cr (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Kenmed Pharma Private Limited U51909RJ2021PTC074915
Director01 Apr 20222021₹1.79 Cr (FY 2024)Active

Board colleagues of Mahesh Pareek

Directorship timeline

Open interactive timeline →
Kenmed Pharma Private Limited
Premium access

Shareholding and investment profile for Mahesh Pareek

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Mahesh Pareek

Mahesh Pareek currently holds 1 directorship: Kenmed Pharma Private Limited (Director, since 01 Apr 2022, revenue ₹1.79 Cr (FY 2024)).

Mahesh Pareek was first appointed on 01 Apr 2022 as Director at Kenmed Pharma Private Limited.

The current boards of Mahesh Pareek's companies include Ashish Gupta (Kenmed Pharma Private Limited), Harish Gupta (Kenmed Pharma Private Limited), Laxman Ram Saini (Kenmed Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available